Transaction #22614 · Form 4 · 0001453687-25-000144
Cartesian Therapeutics, Inc. · Stock award · Stock Option (Right to Buy)
Cartesian Therapeutics, Inc. · Transacted December 16, 2025 · Filed December 18, 2025
What does this filing report?
An SEC Form 4 filing for Cartesian Therapeutics, Inc. records a stock award involving Stock Option (Right to Buy) on December 16, 2025. The reported quantity was 17,200. The filing date is December 18, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Cartesian Therapeutics, Inc.
- Company CIK
- 0001453687
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 17,200
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 17,200
- Ownership description
- Not reported
- SEC acceptance time
- Dec 18, 2025, 5:05 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Bot Adrian Ion ↗
Director
CIK 0002101801
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 17,200
- Conversion / exercise price
- 8.29
- Exercise date
- Not reported
- Expiration date
- December 15, 2035
Filing footnotes & remarks
- F1
- Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on December 16, 2028.
- F2
- This award will vest in 36 equal monthly installments, so that it shall be fully vested on December 16, 2028.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.